Related Experiment Video
Updated: Oct 4, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges
Jocelyn Y Hsu1, Nathan D Seligson1,2,3, John L Hays1,4
1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Purpose:
Soft tissue and bone sarcomas are rare malignancies that exhibit significant pathologic and molecular heterogeneity. Deregulation of the CDKN2A-CCND-CDK4/6-retinoblastoma 1 (Rb) pathway is frequently observed in about 25% of unselected sarcomas and is pathognomonic for specific sarcoma subtypes. This genomic specificity has fueled the clinical evaluation of selective CDK4/6 inhibitors in sarcomas. Here, we highlight successes, opportunities, and future challenges for using CDK4/6 inhibitors to treat sarcoma.
Materials And Methods:
This review summarizes the current evidence for the use of CDK4/6 inhibitors in sarcoma while identifying molecular rationale and predictive biomarkers that provide the foundation for targeting the CDK4/6 pathway in sarcoma. A systematic review was performed of articles indexed in the PubMed database and the National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov). For each sarcoma subtype, we discuss the preclinical rationale, case reports, and available clinical trials data.
Results:
Despite promising clinical outcomes in a subset of sarcomas, resistance to CDK4/6 inhibitors results in highly heterogeneous clinical outcomes. Current clinical data support the use of CDK4/6 inhibitors in subsets of sarcoma primarily driven by CDK4/6 deregulation. When dysregulation of the Rb pathway is a secondary driver of sarcoma, combination therapy with CDK4/6 inhibition may be an option. Developing strategies to identify responders and the mechanisms that drive resistance is important to maximize the clinical utility of these drugs in patients with sarcoma. Potential biomarkers that indicate CDK4/6 inhibitor sensitivity in sarcoma include CDK4, CCND, CCNE, RB1, E2F1, and CDKN2A.
Conclusion:
CDK4/6 inhibitors represent a major breakthrough for targeted cancer treatment. CDK4/6 inhibitor use in sarcoma has led to limited, but significant, early clinical success. Targeted future clinical research will be key to unlocking the potential of CDK4/6 inhibition in sarcoma.
Insights
CDK4/6 inhibitors show early success in treating specific sarcomas. Future research is crucial to overcome resistance and maximize the clinical utility of these targeted therapies for sarcoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Soft tissue and bone sarcomas are rare cancers with diverse pathology and molecular features.
- The cyclin-dependent kinase (CDK)4/6-retinoblastoma 1 (Rb) pathway is frequently dysregulated in approximately 25% of sarcomas, indicating its importance in specific subtypes.
Purpose of the Study:
- To review the current evidence and clinical evaluation of selective CDK4/6 inhibitors for sarcoma treatment.
- To highlight the successes, opportunities, and challenges associated with using CDK4/6 inhibitors in sarcoma therapy.
Main Methods:
- A systematic review of relevant literature was conducted using PubMed and the National Institutes of Health Clinical Trials Registry.
- Analysis included preclinical data, case reports, and clinical trial findings for various sarcoma subtypes.
Main Results:
- CDK4/6 inhibitors have demonstrated early clinical success in a subset of sarcomas, particularly those with primary CDK4/6 pathway deregulation.
- Resistance to these inhibitors leads to varied clinical outcomes, necessitating strategies to identify sensitive patients and resistance mechanisms.
- Potential predictive biomarkers for CDK4/6 inhibitor sensitivity include alterations in CDK4, CCND, CCNE, RB1, E2F1, and CDKN2A.
Conclusions:
- CDK4/6 inhibitors represent a significant advancement in targeted cancer therapy, showing promising results in specific sarcoma indications.
- Further targeted clinical research is essential to fully realize the therapeutic potential of CDK4/6 inhibition in sarcoma treatment.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:21Cancer Survival Analysis